PRISM BioLab and Receptor.AI's Collaboration to Transform Drug Discovery Processes

PRISM BioLab Partners with Receptor.AI in Drug Discovery Initiative

On March 12, 2026, PRISM BioLab Co., Ltd. and Receptor.AI Inc. took a significant step forward in the field of pharmaceutical development by announcing their collaboration agreement aimed at enhancing drug discovery processes. This partnership aims to leverage the advanced capabilities of artificial intelligence (AI) alongside PRISM's innovative PepMetics® technology to establish a unique integrated platform that targets complex diseases.

Uniting Expertise for Targeted Solutions

The collaboration combines PRISM's PepMetics® chemistry—known for creating three-dimensional small molecules that simulate specific peptide motifs—with Receptor.AI's sophisticated AI-driven navigation engine. This merger of technology is anticipated to create an arsenal of compounds aimed at addressing intracellular protein–protein interactions (PPIs), membrane proteins, and various complex receptor systems, particularly targeting metabolic diseases like obesity initially.

Dai Takehara, CEO of PRISM BioLab, expressed enthusiasm about the project, stating, "Our PepMetics® library holds the potential for not just targeting intracellular PPI drug discoveries but also membrane proteins—challenging targets for conventional small molecules." This partnership is poised to provide revolutionary methodologies for identifying and optimizing novel therapeutics, paving the way for more effective treatment options.

Innovative Drug Discovery Approach

Receptor.AI's Founder and CEO, Dr. Alan Nafiiev, highlighted the shift from the traditional ‘screening harder’ method to a more intelligent ‘navigating smarter’ approach, which the partnership embodies. The collaboration focuses on achieving breakthroughs not merely by developing clinical candidates but also by showcasing the combined strengths of both companies and moving towards enhancing overall drug discovery methodologies.

The initial phases of the collaboration will center on molecular design focusing on a single receptor target related to metabolic diseases. Utilizing the combined technological capabilities enables pharmaceutical partners to engage in a broader scope rooted in the advanced findings and insights produced from the collaboration.

Emphasizing a Forward-Thinking Philosophy

Both PRISM BioLab and Receptor.AI share a vision of modernizing drug discovery through innovative methods. They aim to build a comprehensive understanding of biological interactions while deploying cutting-edge technologies to improve therapeutic offerings for patients suffering from various health conditions.

The overarching aim of this partnership is to redefine the way drug discovery is approached, with a focus on not just producing results but also nurturing a system that is capable of delivering high-quality therapeutic outcomes.

About PRISM BioLab and Receptor.AI

PRISM BioLab is dedicated to advancing biotechnology by utilizing proprietary PepMetics® technology. This platform specializes in developing small molecule inhibitors for PPIs, aiming to revolutionize treatment for diseases such as cancer and autoimmune conditions.

Receptor.AI, based in the United States, is making pivotal strides in preclinical drug discovery through its generative AI platforms, harnessing the power of data-driven research and computational approaches to meet pressing healthcare challenges.

By forming this collaboration, both companies are not just contributing their individual strengths, but they are also building a dynamic partnership that is expected to set new standards in the ways emerging therapeutics are discovered and developed, ultimately benefiting patients globally. This unique alliance signifies a critical leap towards efficient drug discovery powered by both advanced AI and sophisticated chemistry, representing a bold step toward tackling longstanding challenges within the pharmaceutical landscape.